Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- Pfizer: One of the worlds premier biopharmaceutical companies
Pfizer has your back in the fight against cancer With over 50+ programs, 80+ clinical trials worldwide and 40% of our R D budget dedicated to oncology, we're committed to advancements in cancer care
- Pfizer’s 2025 Priorities: A Roadmap to Innovation and Excellence
Among a series of potential R D program advances in 2025, Pfizer expects 13 Phase 3 program starts, 8 late-stage readouts and 4 regulatory decisions, among which includes several potential mega-blockbuster treatments in oncology, vaccines and obesity
- Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
Pfizer Inc (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management
- Arvinas and Pfizer Announce Positive Topline Results from Phase 3 . . .
NEW HAVEN, Conn and NEW YORK, March 11, 2025 – Arvinas, Inc (Nasdaq: ARVN) and Pfizer Inc (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2
- Careers | Pfizer
We’ve transformed growth and development at Pfizer to ensure that everyone can follow a path to their dream career, whether that’s climbing a traditional ladder or “zig-zagging” their way to a new role
- Pfizer’s year in review | Pfizer 2024 Annual Report
Since 1849, when Charles Pfizer and Charles Erhart founded Pfizer in Brooklyn, New York, we’ve demonstrated a relentless commitment to innovation, taking on some of the world’s greatest health challenges and improving hundreds of millions of lives
- Pfizer Pipeline
With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements that target unmet medical need or represent potential significant commercial opportunities
- Arvinas and Pfizers Vepdegestrant Significantly Improves Progression . . .
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits
|
|
|